TELIX PHARMACEUTICALS LIMITED overview

MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET 1 agent, Zircaix® 2 (TLX250-CDx) for the imaging of kidney cancer in the United States (U.S.), subject to regulatory approval. In preparation for a planned commercial rollout, Telix has contracted with...

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON 1 trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET 2 agent, TLX250-CDx (Zircaix® 3 , 89 Zr-girentuximab), is highly accurate in detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs). In this...

MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer. TLX101 (4-L-[ 131 I]...

MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara™ 1 , 18 F-floretyrosine or 18 F-FET), an investigational PET 2 agent for the characterization of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Given the...

MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech) and Telix Manufacturing Solutions...

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities PR Newswire MELBOURNE, Australia, Aug. 22, 2024 MELBOURNE, Australia , Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024 . All figures are in AU$ unless otherwise stated. [1] H1 2024 financial highlights Total Group revenue of $364.0 million , an increase of 65% compared to H1...

MELBOURNE, Australia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated. 1 H1 2024 financial highlights Total Group revenue of $364.0 million, an increase of 65% compared to H1 2023, reflecting continued growth in sales of its prostate cancer imaging agent, Illuccix ® in the United States (U.S.), now in its second full year of...

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara™ 1 , 18 F-floretyrosine or 18 F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed. Amino acid PET is included in U.S. and European...